The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials. Patients and Methods: KRAS mutations were detected using polymerase chain reaction on DNA from tumor sections collected in a phase III mCRC trial comparing panitumumab monotherapy to best supportive care (BSC). We tested whether the effect of panitumumab on progression-free survival (PFS) differed by KRAS status. Results: KRAS status was ascertained in 427 (92%) of 463 patients (208 panitumumab, 219 BSC). KRAS mutations were found in 43% of patients. The treatment effect on PFS in the wild-type (WT) KRAS group (hazard ratio [HR], 0.45; 95% CI: 0.34 to 0.59) was significantly greater (P < .0001) than in the mutant group (HR, 0.99; 95% CI, 0.73 to 1.36). Median PFS in the WT KRAS group was 12.3 weeks for panitumumab and 7.3 weeks for BSC. Response rates to panitumumab were 17% and 0%, for the WT and mutant groups, respectively. WT KRAS patients had longer overall survival (HR, 0.67; 95% CI, 0.55 to 0.82; treatment arms combined). Consistent with longer exposure, more grade III treatment-related toxicities occurred in the WT KRAS group. No significant differences in toxicity were observed between the WT KRAS group and the overall population. Conclusion: Panitumumab monotherapy efficacy in mCRC is confined to patients with WT KRAS tumors. KRAS status should be considered in selecting patients with mCRC as candidates for panitumumab monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux®) in metastatic colorectal cancer (mCRC).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Amado et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [22]
In the citing paper
“Although exclusion of patients with KRAS (exon 2)-mutant tumors has arithmetically increased the percentage of responders up to 13–17 %”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
In the citing paper
“most KRAS wild-type tumors still do not respond to anti-EGFR moAbs [26, 32].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationMoore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)
Newton, C. R., Graham, A., Heptinstall, L., Powell, S. J., Summers, C. W., Kalsheker, N. A., Smith, J. C., & Markham, A. F. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.7.2503 · Cited by 2,483
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,014
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 82
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer
Stiegelbauer, V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i33.11727 · Cited by 83
Epidermal growth factor receptor in relation to tumor development: EGFR‐targeted anticancer therapy
Okamoto, I. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07449.x · Cited by 81
An Evaluation of Pharmacists‘ Expectations Towards Pharmacogenomics
de Denus, S., Letarte, N., Hurlimann, T., Lambert, J.-P., Lavoie, A., Robb, L. J., Sheehan, N. L., Turgeon, J., & Vadnais, B. (2013) · Pharmacogenomics · doi:10.2217/pgs.12.197 · Cited by 82
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Adackapara, C., Sholl, L. M., Barletta, J. A., & Hornick, J. L. (2013) · Histopathology · doi:10.1111/his.12154 · Cited by 81
Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
Kotoula, V., Charalambous, E., Biesmans, B., Malousi, A., Vrettou, E., Fountzilas, G., & Karkavelas, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007746 · Cited by 80
Pillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 82
Paz-Ares, L. G., Gomez‐Roca, C., Delord, J., Cervantes, A. M. R., Markman, B., Corral, J., Soria, J., Bergé, Y., Roda, D., Russell-Yarde, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8888 · Cited by 80
Activation of RAS family members confers resistance to ROS1 targeting drugs
Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80
Cutsem, E. V., Dicato, M. A., Arber, N., Berlin, J. D., Cervantes, A. M. R., Ciardiello, F., de Gramont, A., Díaz‐Rubio, E., Ducreux, M. P., Geva, R., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq273 · Cited by 80
Targeted therapies in colorectal cancer—an integrative view by PPPM
Hagan, S., Orr, M. C. M., & Doyle, B. J. (2013) · The EPMA Journal · doi:10.1186/1878-5085-4-3 · Cited by 88
Current Progress in Targeted Therapy for Colorectal Cancer
Ortega, J., Vigil, C. E., & Chodkiewicz, C. (2010) · Cancer Control · doi:10.1177/107327481001700102 · Cited by 80
Tol, J., Dijkstra, J. R., Vink-Börger, M. E., Nagtegaal, I. D., Punt, C. J. A., van Krieken, J. H., & Ligtenberg, M. J. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00788.x · Cited by 81
The Importance of Biopsy in the Era of Molecular Medicine
Ziv, E., Durack, J. C., & Solomon, S. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000228 · Cited by 80
Systemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 80
Filip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 86
ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development
Fang, L., Lu, W., Choi, H. H., Yeung, S. J., Tung, J.-Y., Hsiao, C., Fuentes‐Mattei, E., Menter, D. G., Chen, C., Wang, L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.004 · Cited by 79
Individualization of cancer treatment from radiotherapy perspective
Yaromina, A., Krause, M., & Baumann, M. A. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.007 · Cited by 79
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Dempke, W. C. M., & Heinemann, V. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.11.038 · Cited by 78
Hoyle, M., Crathorne, L., Peters, J., Jones-Hughes, T., Cooper, C., Napier, M., Tappenden, P., & Hyde, C. (2013) · Health Technology Assessment · doi:10.3310/hta17140 · Cited by 76
de Castro, D. G., Angulo, B., Gomez, B., Mair, D., Martinez, R., Suárez‐Gauthier, A., Shieh, F., Velez, M., Brophy, V. H., Lawrence, H. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.259 · Cited by 79
RAS and BRAF in metastatic colorectal cancer management
Gong, J., Cho, M. T., & Fakih, M. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.06.12 · Cited by 84
Epidermal Growth Factor Receptor Targeted Therapy in Stages III and IV Head and Neck Cancer
Cripps, C., Winquist, E., deVries, M., Stys‐Norman, D., Gilbert, R. W., & the Head and Neck Cancer Disease Site Group (2010) · Current Oncology · doi:10.3747/co.v17i3.520 · Cited by 79
Köhne, C., Hofheinz, R., Mineur, L., Letocha, H., Greil, R., Thaler, J., Fernebro, E., Gamelin, E. C., DeCosta, L., & Karthaus, M. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1061-6 · Cited by 80
Peeters, M., & Price, T. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.08.002 · Cited by 80
Self-citationCircadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer
Fang, L., Yang, Z., Zhou, J., Tung, J.-Y., Hsiao, C., Wang, L., Deng, Y., Wang, P., Wang, J., & Lee, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0030 · Cited by 82
The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioğlu, S., Tsai, C., Jang, H., Gürsoy, A., & Keskin, Ö. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
Cryopreservation of human colorectal carcinomas prior to xenografting
Linnebacher, M., Maletzki, C., Ostwald, C., Klier, U., Krohn, M., Klar, E., & Prall, F. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-362 · Cited by 78
Nayak, T. K., Garmestani, K., Milenic, D. E., & Brechbiel, M. W. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094169 · Cited by 78
Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
Petrelli, F., Borgonovo, K., Cabiddu, M., Ghilardi, M., & Barni, S. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1149-0 · Cited by 78
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 81
Dienstmann, R., Patnaik, A., Garcia-Carbonero, R., Cervantes, A., Benavent, M., Roselló, S., Tops, B. B. J., van der Post, R. S., Argilés, G., Skartved, N. J. Ø., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1432 · Cited by 77
Overview of Systemic Therapy for Colorectal Cancer
Goodwin, R. A., & Asmis, T. R. (2009) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0029-1242465 · Cited by 78
Muscarinic receptor agonists stimulate human colon cancer cell migration and invasion
Belo, A., Cheng, K., Chahdi, A., Shant, J., Xie, G., Khurana, S., & Raufman, J. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00306.2010 · Cited by 77
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taïeb, J., Jung, A., Bianchi, A. S., Peeters, M., Seligmann, J. F., Zaanan, A., Burdon, P., Montagut, C. O., & Laurent‐Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 78
Self-citationTowards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine
Xie, L., Ge, X., Tan, H., Xie, L., Zhang, Y., Hart, T. D., Yang, X., & Bourne, P. E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003554 · Cited by 75
Characterization of rare transformingKRASmutations in sporadic colorectal cancer
Tong, J. H., Lung, R. W. M., Sin, F. M., Law, P. P. Y., Kang, W., Chan, A. W. H., Ma, B. B. Y., Mak, T. W. C., Ng, S. S., & To, K. F. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28550 · Cited by 76
Saxena, A., Meteling, B., Kapoor, J., Golani, S., Morris, D. L., & Bester, L. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4164-x · Cited by 76
Guren, T. K., Thomsen, M., Kure, E. H., Sørbye, H., Glimelius, B. L. G., Pfeiffer, P., Osterlund, P. J., Sigurdsson, F., Lothe, I. M. B., Dalsgaard, A. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.93 · Cited by 75
Precision oncology: A new era of cancer clinical trials
Renfro, L. A., An, M., & Mandrekar, S. J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.015 · Cited by 76
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 74
Optimal targeting of the mTORC1 kinase in human cancer
Lane, H. A., & Breuleux, M. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.01.016 · Cited by 75
Adam, R. A., Haller, D. G., Poston, G. J., Raoul, J., Spano, J., Tabernero, J. M., & Cutsem, E. V. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq043 · Cited by 74
Spindler, K.-L. G., Pallisgaard, N., Rasmussen, A. A., Lindebjerg, J., Andersen, R. F., Crüger, D. G., & Jakobsen, A. K. M. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn712 · Cited by 78
Li, X., Yang, T., Li, C. S., Song, Y., Lou, H. X., Guan, D., & Jin, L. (2018) · Theranostics · doi:10.7150/thno.22502 · Cited by 75
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 76
Clinical utility of whole-genome sequencing in precision oncology
Rosenquist, R., Cuppen, E. P. J. G., Buettner, R., Caldas, C., Dreau, H. M.-P., Elemento, O., Frederix, G., Grimmond, S. M., Haferlach, T., Jobanputra, V., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.018 · Cited by 73
Sundström, M., Edlund, K., Lindell, M., Glimelius, B. L. G., Birgisson, H., Micke, P., & Botling, J. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-660 · Cited by 74
Fujiyoshi, K., Yamamoto, G., Takahashi, A., Arai, Y., Yamada, M., Kakuta, M., Yamaguchi, K., Akagi, Y., Nishimura, Y., Sakamoto, H., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5323 · Cited by 75
Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer
Ross, J. S., Torres‐Mora, J., Wagle, N., Jennings, T. A., & Jones, D. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcp2y8ktdpoaorh · Cited by 74
Cserepes, M., Ostoros, G., Lohinai, Z., Rásó, E., Barbai, T., Tı́már, J., Rózsás, A., Moldvay, J., Kovalszky, I., Fábián, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.001 · Cited by 75
Torres-Roca, J. F. (2012) · Personalized Medicine · doi:10.2217/pme.12.55 · Cited by 81
Élez, E., Argilés, G., & Tabernero, J. M. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0369-x · Cited by 72
Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters
Lim, S. B., Lim, C. T., & Lim, W. (2019) · Cancers · doi:10.3390/cancers11101595 · Cited by 73
The road to resistance: EGFR mutation and cetuximab
Bardelli, A., & Janne, P. A. (2012) · Nature Medicine · doi:10.1038/nm.2646 · Cited by 71
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab
Stremitzer, S., Stift, J., Gruenberger, B., Tamandl, D., Aschacher, T., Wolf, B., Wrba, F., & Gruenberger, T. (2012) · British journal of surgery · doi:10.1002/bjs.8909 · Cited by 72
More is less—combining targeted therapies in metastatic colorectal cancer
Punt, C. J. A., & Tol, J. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.168 · Cited by 76
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab
Nayak, T. K., Regino, C. A. S., Wong, K. J., Milenic, D. E., Garmestani, K., Baidoo, K. E., Szajek, L. P., & Brechbiel, M. W. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1370-z · Cited by 75
Kosmidou, V., Oikonomou, E., Vlassi, M., Avlonitis, S., Katseli, A., Tsipras, I., Mourtzoukou, D., Kontogeorgos, G., Zografos, G., & Pintzas, A. (2013) · Human Mutation · doi:10.1002/humu.22496 · Cited by 74
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 75
Kim, S. S., Cho, Y. M., Kim, G. H., Kee, K.-H., Kim, H., Kim, K. M., Kim, J., & Choi, C. (2020) · Modern Pathology · doi:10.1038/s41379-019-0420-8 · Cited by 73
Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
Fiore, F. D., Sesboüé, R., Michel, P., Sabourin, J., & Frébourg, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6606008 · Cited by 76
Han, C., Li, F., Ma, J., & Zou, H. (2012) · Cancer Investigation · doi:10.3109/07357907.2012.732159 · Cited by 74
Next generation oncology drug development: opportunities and challenges
Gutierrez, M. E., Kummar, S., & Giaccone, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.38 · Cited by 71
18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
Krause, B. J., Herrmann, K., Wieder, H. A., & Büschenfelde, C. M. Z. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057232 · Cited by 71
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2029 · Cited by 72
Reovirus: A Targeted Therapeutic—Progress And Potential
Maitra, R., Ghalib, M. H., & Goel, S. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0157 · Cited by 70
Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer
Yörüker, E. E., Holdenrieder, S., & Deligezer, U. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.01.016 · Cited by 72
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Carethers, J. M. (2008) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08093607 · Cited by 71
Basavaraj, C., Sierra, P., Shivu, J., Melarkode, R., Monte, E., & Nair, P. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.7.12793 · Cited by 71
Xy, Y., Guan, M., Vigil, D., Der, C. J., Lowy, D. R., & Popescu, N. C. (2009) · Oncogene · doi:10.1038/onc.2008.498 · Cited by 70
Targeting the EGFR and the PKB pathway in cancer
Klein, S., & Levitzki, A. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.006 · Cited by 70
Regulation of 18F-FDG Accumulation in Colorectal Cancer Cells with Mutated KRAS
Iwamoto, M., Kawada, K., Nakamoto, Y., Itatani, Y., Inamoto, S., Toda, K., Kimura, H., Sasazuki, T., Shirasawa, S., Okuyama, H., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.142927 · Cited by 74
EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments
Kataoka, H. (2009) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2009.10.002 · Cited by 70
Personalized medicine: hope or hype?
Salari, K., Watkins, H. C., & Ashley, E. A. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs112 · Cited by 76
Mosakhani, N., Lahti, L., Borze, I., Karjalainen‐Lindsberg, M., Sundström, J. T. T., Ristamäki, R., Osterlund, P. J., Knuutila, S., & Sarhadi, V. K. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2012.08.003 · Cited by 72
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials
Alosh, M., Huque, M. F., Bretz, F., & D’Agostino, R. B. (2016) · Statistics in Medicine · doi:10.1002/sim.7167 · Cited by 69
Topham, J. T., O'Callaghan, C. J., Feilotter, H., Kennecke, H. F., Lee, Y. S., Li, W., Banks, K. C., Quinn, K., Renouf, D. J., Jonker, D. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00364 · Cited by 70
Nimotuzumab: beyond the EGFR signaling cascade inhibition
Mazorra, Z., Chao, L., Lavastida, A., Sanchez, B., Ramos, M., Iznaga, N., & Crombet, T. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.008 · Cited by 74
Therapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 72
Zouhairi, M. E., Charabaty, A., & Pishvaian, M. J. (2011) · PubMed Central · Cited by 68
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
Eng, C. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.16 · Cited by 70
Methods of overcoming treatment resistance in colorectal cancer
Temraz, S. N., Mukherji, D., Alameddine, R. S., & Shamseddine, A. I. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.08.015 · Cited by 69
Pitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., Leong, S., Coldren, C. D., Hirsch, F. R., Varella‐Garcia, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3191 · Cited by 73
Role of targeted agents in metastatic colorectal cancer
Prenen, H., Vecchione, L., & Cutsem, E. V. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0281-x · Cited by 70
Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection
Stallard, N., Hamborg, T., Parsons, N., & Friede, T. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.857238 · Cited by 69
Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffin-embedded tumor tissues
Dufort, S., Richard, M., & de Fraipont, F. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.05.027 · Cited by 69
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
Baas, J. M., Krens, L. L., Guchelaar, H., Ouwerkerk, J., de Jong, F. A., Lavrijsen, A. P. M., & Gelderblom, H. A. J. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.09.004 · Cited by 68
Adelstein, B., Dobbins, T., Harris, C. A., Marschner, I. C., & Ward, R. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.031 · Cited by 72
Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez‐Barriocanal, Á., Arango, D., Conde, J. P., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.017 · Cited by 71
Garrido‐Laguna, I., McGregor, K., Wade, M. L., Weis, J. R., Gilcrease, W., Burr, L., Soldi, R., Jakubowski, L., Davidson, C., Morrell, G., et al. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9947-6 · Cited by 69
Personalized therapies in the cancer "omics" era
Ocaña, A., & Pandiella, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-202 · Cited by 68
Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs
Amir, E., Šeruga, B., Martínez‐López, J., Kwong, R. C., Pandiella, A., Tannock, I. F., & Ocaña, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2393 · Cited by 68
Joseph, L. J., Cankovic, M., Caughron, S. K., Chandra, P., Emmadi, R., Hagenkord, J. M., Hallam, S., Jewell, K. E., Klein, R. D., Pratt, V. M., et al. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.05.007 · Cited by 68
Khan, K. H., Valeri, N., Dearman, C., Rao, S., Watkins, D. J., Starling, N., Chau, I., & Cunningham, D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.09.001 · Cited by 70
Suenaga, M., Mizunuma, N., Matsusaka, S., Shinozaki, E., Ozaka, M., Ogura, M., & Yamaguchi, T. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s85567 · Cited by 68
Braig, F., März, M., Schieferdecker, A., Schulte, A., Voigt, M., Stein, A., Grob, T. J., Alawi, M., Indenbirken, D., Kriegs, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3574 · Cited by 67
Galsky, M. D., Hoff, D. D. V., Neubauer, M., Anderson, T., Fleming, M. T., Nagarwala, Y. M., Mahoney, J. M., Midwinter, D., Vocila, L., & Zaks, T. Z. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9541-0 · Cited by 68
Metadata
- Authors
- Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., & Chang, D. D.
- Affiliations
- Ghent University Hospital (BE)
- Amgen (United States) (US)
- From Amgen Inc, Thousand Oaks, CA; Ghent University Hospital, Ghent, Belgium; University Hospital Gasthuisberg, Leuven, Belgium; and the Ospedale Niguarda Ca’ Granda, Milan, Italy
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1626-1634
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106789440
- Cited by
- 3,207
- References
- 38
- Citations by year
- 2026: 32 · 2025: 48 · 2024: 59 · 2023: 77 · 2022: 112 · 2021: 123 · 2020: 106 · 2019: 135 · 2018: 131 · 2017: 163 · 2016: 181 · 2015: 253 · 2014: 280 · 2013: 254 · 2012: 288
- FWCI
- 169.59
- Type
- journal article
- Language
- en
- Update notices
- new_edition (2023-06-14)
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- panitumumab, KRAS wild-type, KRAS mutation, metastatic colorectal cancer, anti-EGFR therapy, epidermal growth factor receptor, biomarker selection, progression-free survival, best supportive care, treatment toxicity, patient selection
- MeSH terms
- Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins, Biomarkers, Tumor, Colorectal Neoplasms, Polymerase Chain Reaction, Proto-Oncogene Proteins p21(ras), Disease-Free Survival, ras Proteins, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
